Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
Mori N, Tamaki N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, Kobashi H, Fujii H, Ogawa C, Nonogi M, Arai H, Uchida Y, Urawa N, Narita R, Akahane T, Kondo M, Yasui Y, Tsuchiya K, Izumi N, Kurosaki M. Mori N, et al. Among authors: narita r. Invest New Drugs. 2024 Aug 30. doi: 10.1007/s10637-024-01470-y. Online ahead of print. Invest New Drugs. 2024. PMID: 39212893
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Takaki S, Kurosaki M, Mori N, Tsuji K, Ochi H, Marusawa H, Nakamura S, Tada T, Narita R, Uchida Y, Akahane T, Kondo M, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Ogawa C, Sato T, Tamaki N, Yasui Y, Tsuchiya K, Izumi N. Takaki S, et al. Among authors: narita r. Invest New Drugs. 2023 Apr;41(2):340-349. doi: 10.1007/s10637-023-01349-4. Epub 2023 Mar 30. Invest New Drugs. 2023. PMID: 36995548
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma.
Tamaki N, Mori N, Takaki S, Tsuji K, Tada T, Nakamura S, Ochi H, Mashiba T, Doisaki M, Marusawa H, Kobashi H, Fujii H, Ogawa C, Nonogi M, Arai H, Uchida Y, Urawa N, Narita R, Akahane T, Kondo M, Yasui Y, Tsuchiya K, Izumi N, Kurosaki M. Tamaki N, et al. Among authors: narita r. Anticancer Res. 2024 Sep;44(9):3913-3918. doi: 10.21873/anticanres.17219. Anticancer Res. 2024. PMID: 39197893
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.
Morita A, Tamaki N, Kobashi H, Mori N, Tsuji K, Takaki S, Hasebe C, Akahane T, Ochi H, Mashiba T, Urawa N, Fujii H, Mitsuda A, Kondo M, Ogawa C, Uchida Y, Narita R, Marusawa H, Kubotsu Y, Matsushita T, Shigeno M, Yoshida H, Tanaka K, Okamoto E, Kasai T, Ishii T, Okada K, Kurosaki M, Izumi N. Morita A, et al. Among authors: narita r. JGH Open. 2024 Apr 25;8(4):e13068. doi: 10.1002/jgh3.13068. eCollection 2024 Apr. JGH Open. 2024. PMID: 38681824 Free PMC article.
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.
Tada T, Kurosaki M, Toyoda H, Tamaki N, Yasui Y, Nakamura S, Mori N, Tsuji K, Ochi H, Akahane T, Kobashi H, Fujii H, Marusawa H, Kondo M, Urawa N, Yoshida H, Uchida Y, Morita A, Hasebe C, Mitsuda A, Ogawa C, Narita R, Kubotsu Y, Matsushita T, Shigeno M, Okamoto E, Okada K, Kasai T, Ishii T, Nonogi M, Yasuda S, Koshiyama Y, Kumada T, Izumi N. Tada T, et al. Among authors: narita r. Liver Int. 2024 Nov;44(11):3060-3071. doi: 10.1111/liv.16093. Epub 2024 Sep 2. Liver Int. 2024. PMID: 39223936
TMEFF1 is a neuron-specific restriction factor for herpes simplex virus.
Dai Y, Idorn M, Serrero MC, Pan X, Thomsen EA, Narita R, Maimaitili M, Qian X, Iversen MB, Reinert LS, Flygaard RK, Chen M, Ding X, Zhang BC, Carter-Timofte ME, Lu Q, Jiang Z, Zhong Y, Zhang S, Da L, Zhu J, Denham M, Nissen P, Mogensen TH, Mikkelsen JG, Zhang SY, Casanova JL, Cai Y, Paludan SR. Dai Y, et al. Among authors: narita r. Nature. 2024 Aug;632(8024):383-389. doi: 10.1038/s41586-024-07670-z. Epub 2024 Jul 24. Nature. 2024. PMID: 39048823
Cholesterol-binding motifs in STING that control endoplasmic reticulum retention mediate anti-tumoral activity of cholesterol-lowering compounds.
Zhang BC, Laursen MF, Hu L, Hazrati H, Narita R, Jensen LS, Hansen AS, Huang J, Zhang Y, Ding X, Muyesier M, Nilsson E, Banasik A, Zeiler C, Mogensen TH, Etzerodt A, Agger R, Johannsen M, Kofod-Olsen E, Paludan SR, Jakobsen MR. Zhang BC, et al. Among authors: narita r. Nat Commun. 2024 Mar 29;15(1):2760. doi: 10.1038/s41467-024-47046-5. Nat Commun. 2024. PMID: 38553448 Free PMC article.
109 results